AlphAIAlphAI — Financial news for AI agents
nai500.comAUG 252 min read$STTK

Shattuck Labs Jumps as Two Analysts Start Bullish Coverage

Shattuck Labs (STTK) rose 4.91% after two analysts initiated coverage with positive ratings. TD Cowen rated it buy, while Raymond James gave a strong buy and $18 price target. Both highlighted SL-325, a drug candidate for inflammatory bowel disease, citing its novel mechanism. The company reported $208.3M in cash and expects funding into 2029. Phase 2b trial for SL-325 is set to start in Q3.

Original reporting
nai500.com
Published Aug 25, 2026, 2:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Shattuck Labs Jumps as Two Analysts Start Bullish Coverage — source image
Source · nai500.com
Decision brief

The 30-second read

$STTKBullishMed
01

Why it matters

Analyst initiation adds credibility and may attract institutional interest, supporting the recent price rally.

02

Market read

New analyst coverage and price target provide fresh catalyst for STTK, justifying short-term trading interest.

03

What to watch

Potential dilution from future financing needs and competition in IBD therapeutics.

Relevance 7/10Novelty 6/10Timing: pre-market

Background

Shattuck Labs reported cash of $208.3M and ongoing Phase 1 data for SL-325, a DR3-blocking antibody for IBD.

Company-level read

Ticker impact

$STTKBullishHigh confidence
Context

Two analysts initiated coverage of Shattuck Labs with buy ratings and a $18 price target, driving a 4.91% price jump.

Expected impact

Potential further upside if coverage prompts additional buying.

Evidence & confidence

Coverage is fresh, includes a price target double the recent close, and coincides with a notable intraday move.

Market effects

Sector

Positive signal for clinical-stage biotech sector as analyst coverage may lift peers.

Regional

Limited to US biotech investors.

Global

Minimal global impact beyond niche biotech community.

Counterpoint

What could challenge this read

Coverage may be premature; trial data still early and market could price in risk.

Key entities

  • Company
    Shattuck Labs

    Clinical-stage biotech developing SL-325.

  • Analyst Firm
    TD Cowen

    Initiated coverage with a buy rating.

  • Analyst Firm
    Raymond James

    Issued a strong buy and $18 price target.

Read at source← All news

Related articles

AUG 27
$STTKMed

Strattec Security Corporation Q4 2026 Earnings Call Summary

Strattec Security Corporation reported record annual revenue of $579.4 million for 2026, driven by pricing, cost actions, and operational improvements. The company reorganized its product portfolio and realized $6 million in restructuring savings, expanding gross margin to 16.5%. Strattec anticipates a challenging 2027 with a 2% decline in North American production and targets long-term gross margins of 18% to 20%. The company maintains a debt-free balance sheet with $108.2 million in cash and p

yahoo.com3 min
AUG 12
$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

investing.com4 min
AUG 11
$STTKMed

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent

Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A bi

SEC EDGAR 8-K6 min
AUG 11
$STTKMed

Why is Shattuck Labs stock slipping today?

Shattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.

investing.com5 min